ENTA Logo

Enanta Pharmaceuticals, Inc. (ENTA) 

NASDAQ
Market Cap
$183.44M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
663 of 968
Rank in Industry
371 of 556

Largest Insider Buys in Sector

ENTA Stock Price History Chart

ENTA Stock Performance

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Insider Activity of Enanta Pharmaceuticals, Inc.

Over the last 12 months, insiders at Enanta Pharmaceuticals, Inc. have bought $0 and sold $605,204 worth of Enanta Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Enanta Pharmaceuticals, Inc. have bought $0 and sold $2.77M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,000 shares for transaction amount of $24,445 was made by Gardiner Nathaniel S. (Sr. VP & General Counsel) on 2016‑05‑11.

List of Insider Buy and Sell Transactions, Enanta Pharmaceuticals, Inc.

2024-07-15SaleChief Medical Officer
5,375
0.0355%
$17.08$91,8050.00%
2024-07-12SaleChief Medical Officer
2,271
0.0132%
$15.04$34,1560.00%
2024-07-11SaleChief Medical Officer
4,299
0.0251%
$15.07$64,7860.00%
2024-06-17SaleChief Product Strategy Officer
7,266
0.0315%
$12.33$89,590-2.15%
2023-12-13Saledirector
15,295
0.0684%
$9.12$139,490+28.58%
2023-12-05SalePresident and CEO
7,230
0.0351%
$9.63$69,625+31.12%
2023-12-05SaleSr. VP, R&D & CSO
2,412
0.0117%
$9.63$23,228+31.12%
2023-12-05SaleSr. VP, Finance & Admin. & CFO
2,412
0.0117%
$9.63$23,228+31.12%
2023-12-05SaleSr. VP & General Counsel
2,412
0.0117%
$9.63$23,228+31.12%
2023-12-05SaleSr. VP, New Prod. Strat. & Dev
2,125
0.0103%
$9.63$20,464+31.12%
2023-12-05SaleSr. VP, Business Dev.
2,125
0.0103%
$9.63$20,464+31.12%
2023-12-05SaleSr. VP & CMO
534
0.0026%
$9.63$5,142+31.12%
2023-03-15SaleSr. VP & CSO
13,925
0.0661%
$44.45$618,960-67.56%
2023-03-15SaleTreasurer and CFO
10,440
0.0495%
$44.43$463,802-67.56%
2023-03-13SalePresident and CEO
27,912
0.133%
$45.16$1.26M-67.30%
2023-02-09SaleTreasurer and CFO
5,000
0.0241%
$53.76$268,816-70.01%
2022-12-16SalePresident and CEO
30,000
0.1421%
$44.72$1.34M-48.24%
2022-04-01SaleSr. VP & Chief Medical Officer
18,076
0.0872%
$71.71$1.3M-31.68%
2022-03-21Sale
2,676
0.0131%
$66.70$178,489-25.35%
2022-03-02SaleSr. VP & Chief Medical Officer
12,481
0.0609%
$70.07$874,544-27.80%

Insider Historical Profitability

11.84%
Luly Jay R.President and CEO
806793
3.8067%
$8.66017
Or Yat SunSr. VP, R&D & CSO
370695
1.749%
$8.66018
MELLETT PAUL JSr. VP, Finance & Admin. & CFO
93549
0.4414%
$8.66020
Gardiner Nathaniel S.Sr. VP & General Counsel
68154
0.3216%
$8.6632+9.2%
Luu BrendanSr. VP, Business Dev.
36736
0.1733%
$8.6601
Kieffer Tara LynnChief Product Strategy Officer
32341
0.1526%
$8.6602
Rottinghaus Scott T.Chief Medical Officer
21717
0.1025%
$8.6604
Vance Terrydirector
5800
0.0274%
$8.6621+8.96%
Goldberg Marc E.director
547606
2.5837%
$8.6603
SCHUHSLER HELMUT
380487
1.7952%
$8.6613+19.31%
TVM V LIFE SCIENCE VENTURES GMBH & CO KG10 percent owner
276999
1.307%
$8.6617+19.31%
Adda NathalieSr. VP & Chief Medical Officer
47191
0.2227%
$8.66014
AFTING ERNST-GUENTERdirector
17287
0.0816%
$8.6601
SAINTS CAPITAL GRANITE, L.P.10 percent owner
16904
0.0798%
$8.6618+19.31%
Ocain TimSenior Vice President
6127
0.0289%
$8.6601
CARTER BRUCE L A
3324
0.0157%
$8.6604
Verdine Gregory L.director
3324
0.0157%
$8.6610+19.31%
Buckley Stephen Jr.director
2000
0.0094%
$8.6630+6.42%
Golumbeski Georgedirector
0
0%
$8.6603

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Farallon Capital$36.58M9.892.1M+3.46%+$1.22M0.26
Morgan Stanley$35.71M9.662.05M+74.34%+$15.23M<0.01
The Vanguard Group$33.66M9.11.93M+7.49%+$2.34M<0.01
BlackRock$32.11M8.681.84M-4.94%-$1.67M<0.01
Armistice Capital Llc$21.58M5.841.24M-40.12%-$14.46M0.07
Krensavage Asset Management LLC$19.64M5.311.12M+51.39%+$6.67M9.91
Marshall Wace$16.61M4.49951,062New+$16.61M0.02
Northern Trust$16.3M4.41933,356-0.23%-$37,312.02<0.01
Caligan Partners LP$14.98M4.05858,070New+$14.98M3.96
Acadian Asset Management$14.91M4.03853,896+1.3%+$191,183.130.05
Millennium Management LLC$12.33M3.34706,248-7.7%-$1.03M0.01
Assenagon Asset Management S.A.$10.19M2.76583,6580%+$00.03
Soleus Capital Management, L.P.$10.14M2.74580,546New+$10.14M0.04
D. E. Shaw & Co.$9.96M2.69570,246-10.64%-$1.19M0.01
Renaissance Technologies$9.19M2.48526,100-5.8%-$565,722.110.02
Bank of America$9.02M2.44516,366+4,111.79%+$8.8M<0.01
Geode Capital Management$7.72M2.09442,072+2.99%+$224,124.97<0.01
State Street$7.4M2423,965-0.39%-$29,245.50<0.0001
Boothbay Fund Management LLC$6.78M1.84388,600New+$6.78M0.22
Tang Capital Management, LLC$5.24M1.42300,0000%+$00.02
Two Sigma Advisers LP$4.92M1.33282,000-3.03%-$153,648.000.01
Two Sigma$4.49M1.22257,309-22.55%-$1.31M0.01
Ubs Asset Management Americas Inc$3.63M0.98208,089-7.13%-$279,010.80<0.01
Jacobs Levy Equity Management$3.4M0.92194,730-65.29%-$6.4M0.01
Dimensional Fund Advisors$3.3M0.89189,256+5.4%+$169,239.74<0.01
Sio Capital Management LLC$3.09M0.84177,004New+$3.09M1.11
Prudential Financial$3.01M0.81172,264-11%-$371,897.95<0.01
Charles Schwab$2.81M0.76161,000+9.28%+$238,660.74<0.01
JPMorgan Chase$2.41M0.65138,047-8.47%-$223,034.08<0.0001
AQR Capital$1.92M0.52109,706-46.03%-$1.63M<0.01
Qube Research & Technologies$1.79M0.49102,625-45.65%-$1.51M<0.01
Trexquant Investment LP$1.67M0.4595,639-19.37%-$401,108.590.03
Goldman Sachs$1.58M0.4390,690-51.41%-$1.68M<0.0001
Nuveen$1.56M0.4289,387+60.75%+$589,798.79<0.0001
SEI Investments Company$1.54M0.4288,1550%+$0<0.01
Federated Hermes$1.54M0.4288,172-33.8%-$785,996.76<0.01
BNY Mellon$1.14M0.3165,196-10.23%-$129,727.33<0.0001
Citadel Advisors LLC$970,130.000.2655,563-16.38%-$190,017.18<0.01
Connor Clark & Lunn Investment Management Ltd$779,222.000.2144,629+7.89%+$56,989.42<0.01
Invesco$759,492.000.2143,499+115%+$406,241.53<0.0001
PDT Partners$693,633.000.1939,727-37.17%-$410,274.830.05
Fidelity Investments$688,291.000.1939,421+28.55%+$152,879.84<0.0001
Pennant Capital Management Llc$612,846.000.1735,1000%+$00.1
RhumbLine Advisers$576,479.000.1633,018+2.18%+$12,291.51<0.01
Ameriprise Financial$556,503.000.1531,873-65.95%-$1.08M<0.0001
Franklin Templeton Investments$507,493.000.1429,066New+$507,493.00<0.0001
AllianceBernstein$487,658.000.1327,9300%+$0<0.0001
Cubist Systematic Strategies$477,483.000.1327,347-66.96%-$967,642.08<0.01
Point72 Asia Singapore Pte Ltd$440,163.000.1225,210+2,000.83%+$419,211.170.04
Wells Fargo$434,910.000.1224,909+303.19%+$327,042.40<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.